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episode initiation. The date of ﬁrst mania-related visit after
depression was the index date of manic-switching for cases and
a random date was assigned for controls. Based on the pharmacy
records, 2050 patients were established having treatment of anti-
depressant monotherapy, mood stabilizer monotherapy, or anti-
depressant-mood stabilizer combination therapy within 30 days
prior to the index date. A logistic regression with difference-
in-difference approach was employed to predict the probabilities
of having manic-switching by different types of treatment.
RESULTS: Patients with antidepressant monotherapy and anti-
depressant-mood stabilizer combination therapy were 31% (n =
87) and 29% (n = 82) in the case group and 43% (n = 768) and
27% (n = 481) in the control group. Using logistic regression to
adjust for patient demographics, clinical-related and health-
related variables, the odds ratios for having manic-switching 
in relation to antidepressant monotherapy and antidepressant-
mood stabilizer combination therapy were 2.71 (95% CI:
1.32–5.56; p < 0.01) and 1.51 (95% CI: 0.81–2.81; p = 0.20)
respectively, compared to mood stabilizer monotherapy. CON-
CLUSIONS: This study further validates the national practice
guidelines for bipolar disorder with a case-control study design,
which does not have the study limitations of typical intent-to-
treat approach. Similar results were identiﬁed, indicating a risk
of induced manic-switching by antidepressant monotherapy yet
not by antidepressant-mood stabilizer combination therapy with
second-generation antidepressants.
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OBJECTIVES: Newer atypical antipsychotic medications were
recently approved by the FDA for treatment of bipolar disorder.
Although cost-effective pharmacotherapy can signiﬁcantly lower
total medical utilization and costs, economic evaluation studies
of pharmacotherapy in bipolar disorder are limited, particularly
for aytypical antipsychotics. This report reviews and identiﬁes
gaps in the current literature regarding impact of pharma-
cotherapy on health care utilization and costs among bipolar
patients. METHODS: A literature search was conducted using
Medline, CINHAL, International Pharmaceutical Abstracts and
Cochrane Collaborative databases for studies published between
January, 1990 and November, 2004. Abstracts presented at
American Psychiatric Association, National Institute of Mental
Health, and International Society of Pharmacoeconomics and
Outcomes Research were also examined. Articles were reviewed
to determine relevance to health care cost and utilization out-
comes associated with bipolar disorder pharmacotherapy.
RESULTS: The systematic search identiﬁed two randomized con-
trolled trials, two studies using administrative claims databases,
two studies using retrospective chart reviews and one study using
decision-modeling. Two studies reported that atypical antipsy-
chotic olanzapine reduced hospitalizations as compared to
placebo and typical antipsychotics. There were no studies com-
paring outcomes between different atypical antipyschotics for
bipolar disorder. Studies evaluating multiple endpoints between
ﬁrst-line pharmacotherapy and combinations of adjunct phar-
macotherapy were also lacking. Divalproex exhibited better cost
and utilization outcomes as compared to other pharmacothera-
pies (olanzapine, lithium and carbamazepine). Reduction in total
direct costs of bipolar disorder with use of any pharmacother-
apy was mostly attributable to reduced hospital stay. CON-
CLUSIONS: It is difﬁcult to compare utilization and cost
outcomes between pharmacotherapies due to the lack of head-
to-head studies, differences in research design and population
characteristics, and lack of cost-effectiveness studies determining
relative value of each pharmacotherapy for bipolar disorder.
Comprehensive evaluations of the impact of therapy on differ-
entiated economic endpoints relevant to practice policies (drug
costs, outpatient costs, hospitalizations, emergency room visits)
are needed.
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OBJECTIVES: To evaluate the effect of the July, 2001 prescrip-
tion limit policy change in the South Carolina Medicaid program
on the utilization of health care services and their related costs
for adult Medicaid recipients diagnosed with schizophrenia 
or bipolar disorder. METHODS: A retrospective cohort study
design, identifying subjects with schizophrenia and bipolar dis-
order compared their utilization of health care services and asso-
ciated costs 18-months before and after the policy change (July,
2001). Eligible patients were age 21 or older, had a qualifying
diagnosis on a hospital or ambulatory claim, and a prescription
medication for their diagnosis within 90 days (+/-) of their 1998
or 1999 enrollment date. Total health care cost and service uti-
lization were estimated by ordinary least squares regres-
sion models and the results contrasted with panel regression
methods due to the short time series. Predictor variables were
demographics, inpatient hospitalization, and comorbidities.
RESULTS: OLS and panel estimation show an increase in total
cost and the number of ambulatory, hospital, prescription, and
nursing home claims after the policy change. Panel estimation
shows a positive monthly trend in the post period for all claims.
CONCLUSIONS: The policy change resulting in an increase in
average monthly patient prescription cost is associated with
increases in total cost of care and overall health care utilizations.
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OBJECTIVES: When conducting analysis using observational
data, there is often selection bias for which we must account for
in order to adjust for pre-treatment differences between groups
in baseline characteristics. This study compared the ordinary
regression, propensity score weighting, propensity score match-
ing, and difference-in-difference (DD) methods while addressing
the impact of second-generation antidepressant use in adult
patients with bipolar disorder. METHODS: A logit model was
developed, as an ordinary approach, to predict the probability
of having post-index mania-related visits from treatment types,
controlling for individual demographics, clinical-related vari-
ables, health-related variables, and pre-index mania-related
visits, serving as the baseline disease severity of bipolar disorder.
The propensity score method added more bipolar severity vari-
ables to predict the propensity to be with one treatment type,
without the problem of over-parameterization in the outcome
model. Both weighting and greedy matching approaches were
applied after the ﬁrst-stage propensity score model achieved the
covariates balancing. For DD model, a logistic regression was
